Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Update on Clostridium difficile-induced colitis, Part 1

C M Reinke1, C R Messick

  • 1Department of Clinical Pharmacy Practice, School of Pharmacy, Auburn University, AL 36849-5502.

American Journal of Hospital Pharmacy
|July 15, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Postantibiotic effects and bactericidal activities of clarithromycin-14-hydroxy-clarithromycin, versus those of amoxicillin-clavulanate, against anaerobes.

Antimicrobial agents and chemotherapy·2000
Same author

Modified time-kill assay against multidrug-resistant Enterococcus faecium with novel antimicrobial combinations.

The Journal of antimicrobial chemotherapy·1999
Same author

In-vitro activity of polyhexamethylene biguanide (PHMB) against fungal isolates associated with infective keratitis.

The Journal of antimicrobial chemotherapy·1999
Same author

In vitro activity of RPR 106972 alone and in combination with vancomycin, ampicillin, and gentamicin against multidrug-resistant enterococci.

Diagnostic microbiology and infectious disease·1998
Same author

Levofloxacin and sparfloxacin: new quinolone antibiotics.

The Annals of pharmacotherapy·1998
Same author

Pharmacoeconomic analysis of ampicillin-sulbactam versus cefoxitin in the treatment of intraabdominal infections.

Pharmacotherapy·1998
Same journal

National health care reform, Part 2: Response to pharmacists.

American journal of hospital pharmacy·1994
Same journal

Validity of originality assessment.

American journal of hospital pharmacy·1994
Same journal

Unit dose dispensing of chromic phosphate P 32 suspension.

American journal of hospital pharmacy·1994
Same journal

Hydralazine injection still available.

American journal of hospital pharmacy·1994
Same journal

Improved extemporaneous formulation of cyclosporine ophthalmic drops.

American journal of hospital pharmacy·1994
Same journal

Paclitaxel diluent and the case of the slippery spike.

American journal of hospital pharmacy·1994
See all related articles

Clostridium difficile-induced colitis (CDIC) is a gastrointestinal infection often linked to antimicrobial use. Understanding its epidemiology, diagnosis, and treatment, including new therapies, is key to reducing its occurrence in hospitals.

Area of Science:

  • Gastroenterology
  • Infectious Diseases
  • Microbiology

Background:

  • Clostridium difficile-induced colitis (CDIC) is a significant gastrointestinal disorder resulting from C. difficile colonization and overgrowth.
  • Hospitalized patients treated with antimicrobials face a higher risk (up to 1%) of developing CDIC compared to community patients (0.003%).
  • Key factors for CDIC include C. difficile source, antimicrobial disruption of colonic flora, cytotoxin production, and patient risk factors like advanced age and severe illness.

Purpose of the Study:

  • To review recent findings on the epidemiology, pathogenesis, clinical manifestations, diagnosis, and treatment of Clostridium difficile-induced colitis (CDIC).
  • To highlight the importance of understanding CDIC for healthcare professionals to improve recognition, treatment selection, and prevention strategies.
  • To discuss current and investigational treatment options for CDIC, including challenges in managing recurrent cases.

Related Experiment Videos

Main Methods:

  • Review of recent literature on Clostridium difficile-induced colitis.
  • Discussion of epidemiological data, risk factors, and clinical presentations.
  • Analysis of diagnostic approaches and therapeutic strategies, including established and emerging treatments.

Main Results:

  • Diarrhea is the predominant symptom of CDIC, with fever and leukocytosis present in severe cases; pseudomembranous plaques are pathognomonic but infrequent.
  • Diagnosis is typically presumptive, based on positive cytotoxin assay in symptomatic patients. Oral metronidazole is the preferred treatment for most cases.
  • Recurrence is common, and investigational treatments like tiacumicin macrolides and Saccharomyces boulardii show promise. Polymerase chain reaction assays may enable faster diagnosis.

Conclusions:

  • Effective management of CDIC requires accurate diagnosis and appropriate treatment, avoiding indiscriminate antimicrobial use.
  • Healthcare professionals must enhance their understanding of CDIC to improve patient outcomes and reduce hospital-acquired infections.
  • Altering antimicrobial use patterns in hospitals is crucial for potentially decreasing the frequency of CDIC.